Drug profile · INN
prasugrel hydrochloride
EFIENT
prasugrel hydrochloride (EFIENT) is a purinergic receptor p2y12 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — prasugrel hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 3
- Programs
- 2
- Data quality
- 0.89
Quick answer
prasugrel hydrochloride (EFIENT) is a purinergic receptor p2y12 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Purinergic receptor P2Y12 antagonist
Primary target: P2Y purinoceptor 12
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is prasugrel hydrochloride?
prasugrel hydrochloride (EFIENT) is a purinergic receptor p2y12 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for prasugrel hydrochloride?
EFIENT is a marketed brand name for prasugrel hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of prasugrel hydrochloride?
prasugrel hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.